Edgewise Therapeutics, INC Schedule 13G passive stakes
Filed when an investor crosses five percent without intending to seek control — the passive counterpart to a 13D.
NASDAQ
Paradigm BioCapital Advisors LP and its affiliates have reported beneficial ownership of 9.5% of Edgewise Therapeutics, Inc. common stock as of June 30, 2026.
NASDAQ
FMR LLC and Abigail P. Johnson have reported beneficial ownership of 5.1% of Edgewise Therapeutics' common stock as of June 30, 2026.
NASDAQ
Janus Henderson Group plc has reported beneficial ownership of 5.5% of Edgewise Therapeutics, Inc. common stock as of March 31, 2026.
NASDAQ
RA Capital Management and its affiliates have disclosed a 9.9% beneficial ownership stake in Edgewise Therapeutics, Inc., totaling 10,428,437 shares of common stock.
NASDAQ
Janus Henderson Group plc has disclosed a 4.7% beneficial ownership stake in Edgewise Therapeutics, Inc., holding 4,979,331 common shares.
NASDAQ
Perceptive Advisors and related entities report a 4.4% beneficial ownership in Edgewise Therapeutics, holding 4,639,949 shares.
NASDAQ
Baker Bros. Advisors and its affiliates have disclosed a 6.9% beneficial ownership stake in Edgewise Therapeutics, Inc., holding over 7.3 million shares.
NASDAQ
Janus Henderson Group plc has reported an increased beneficial ownership of 5.2% in Edgewise Therapeutics, holding 5,503,349 common shares.
NASDAQ
SCHEDULE 13G/A: BlackRock Discloses 5.5% Stake in Edgewise Therapeutics
BlackRock, Inc. has filed an amended Schedule 13G, disclosing a 5.5% beneficial ownership stake in Edgewise Therapeutics Inc., totaling 5,824,866 common shares.
NASDAQ
Perceptive Advisors LLC, Joseph Edelman, and Perceptive Life Sciences Master Fund, Ltd. have jointly reported a 6.1% passive beneficial ownership stake in Edgewise Therapeutics, Inc.
NASDAQ
Janus Henderson Group PLC has filed an amended Schedule 13G, reporting a 5.6% beneficial ownership stake in Edgewise Therapeutics, Inc. as of March 31, 2025.
NASDAQ
Perceptive Advisors LLC, along with Joseph Edelman and Perceptive Life Sciences Master Fund, Ltd., has reported a 5.5% beneficial ownership stake in Edgewise Therapeutics, Inc.
NASDAQ
Janus Henderson Group PLC has filed a Schedule 13G, revealing a significant passive ownership stake of 5.3% in Edgewise Therapeutics, Inc. as of December 31, 2024.
NASDAQ
A group of investment entities and individuals associated with Paradigm BioCapital have disclosed a passive beneficial ownership of 5.0% in Edgewise Therapeutics, Inc. common stock.